CREO
+0.0 · +0.00%
GBX · LSE

Creo Medical Group PLC(CREO) Stock Analysis | Healthcare

GBX --+0.00%
Reward45Moderate
Risk33Moderate
75%Data
Revenue growing 38% YoY
Profitless Growth
Market Cap:62.55M
ⓘ
Reward Rating
45
Moderate
Reward Assessment
75% data coverage
Bottom 25% of stocksView factors
ⓘ
Risk Rating
33
Moderate
Risk Assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on CREO to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Creo Medical Group PLC?

Creo Medical Group PLC, through its subsidiaries, engages in the research, development, manufacture, and sale of medical devices and instruments for clinics and hospitals in the United Kingdom.

AI Brief Pro

The brief on Creo Medical Group PLC

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Creo Medical Group PLC?

Creo Medical Group PLC, through its subsidiaries, engages in the research, development, manufacture, and sale of medical devices and instruments for clinics and hospitals in the United Kingdom. It develops CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with controllable devices delivered through an endoscope. The company is listed on the LSE in UK, operating in the Healthcare sector, with a market capitalisation of 62.55M.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (45)
Company Information
IndustryMedical Devices
Beta0.563
Insider Activity
12M windowAwaiting coverage
LSE director-dealings coverage launching later this year. The data feed is in development.